SER-155

BIOLOGICAL2 trials

Sponsors

Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center

Conditions

Allogeneic Hematopoietic Stem Cell TransplantationDiarrheaEnterocolitis

Phase 1

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

CompletedNCT04995653

Seres Therapeutics, Inc.Allogeneic Hematopoietic Stem Cell Transplantation

Start: 2021-11-24End: 2024-07-23Updated: 2024-10-01

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

RecruitingNCT06801067

Memorial Sloan Kettering Cancer CenterDiarrhea, Enterocolitis

Start: 2025-01-24End: 2027-01-24Target: 15Updated: 2025-12-02

Related Papers

Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT.

Journal of Clinical Oncology2025-05-28

Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).

Journal of Clinical Oncology2024-06-01

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Blood2023-11-02

A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.

Journal of Clinical Oncology2023-06-011 citations

A phase 1b study to evaluate safety, tolerability, pharmacokinetics, and efficacy of SER-155 in adults undergoing hematopoietic stem cell transplantation to reduce the risk of infection and graft versus host disease (NCT04995653).

Journal of Clinical Oncology2022-06-012 citations